精神医学63巻2号

2021年02月発行

展望

遅発性ジスキネジアの最新知見と臨床課題

著者： 堀口淳¹

所属機関： ¹島根大学医学部免疫精神神経学共同研究講座

ページ範囲：P.247 - P.259

抄録　遅発性ジスキネジア(tardive dyskinesia：TD)の最新の臨床知見を概説し，特に早期の発見と対応の重要性を強調した。TDは誤嚥や窒息，あるいは転倒による骨折や頭部外傷といった致死的な結果を招来する副作用であるが，非定型抗精神病薬によるTDの発現率が定型抗精神病薬と比較して低下していないとの指摘に着目した。またTDは患者のQOLの低下や心理社会的問題を惹起することにも注意を喚起した。さらにTDのうち高頻度にみられる口部TDを患者が無自覚でいる場合も多く，そのための早期発見の方法や工夫について，自説を明示した。

参考文献

1)Inada T, Yagi G：Current topics in tardive dyskinesia in Japan. Psychiatry Clin Neurosci 49：239-244, 1995

2)渡邉裕美，駒村隆司，須々田寛，他：医薬品副作用データベースを用いた遅発性ジスキネジアに関する実態調査．臨床精神薬理 22：521-528, 2019

3)Carbon M, Hsieh CH, Kane JM, et al：Tardive dyskinesia prevalence in the period of second-generation antipsychotic use：a meta-analysis. J Clin Psychiatry 78：e264-e278, 2017

4)Carbon M, Kane JM, Leucht S, et al：Tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials：a meta-analysis. World Psychiatry 17：330-340, 2018

5)Correll CU, Schenk EM：Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21：151-156, 2008

6)Li CR, Chung YC, Park TW, et al：Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J Biol Psychiatry 10：919-924, 2009

7)Pardis P, Remington G, Panda R, et al：Clozapine and tardive dyskinesia in patients with schizophrenia：a systematic review. J Psychopharmacol 33：1187-1198, 2019

8)Woods SW, Morgenstern H, Saksa JR, et al：Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications：a prospective cohort study. J Clin Psychiatry 71：463-474, 2010

9)Xiang YT, Wang CY, Si TM, et al：Tardive dyskinesia in the treatment of schizophrenia：the findings of the Research on Asian Psychotropic Prescription Pattern(REAP)survey(2001-2009). Int J Clin Pharmacol Ther 49：382-387, 2011

10)Tang CT, Chua EC, Chew QH, et al：Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region. Asia Pac Psychiatry 12：e12393, 2020

11)Adam UU, Husain N, Haddad PM, et al：Tardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics. Neuropsychiatr Dis Treat 10：1953-1959, 2014

12)Novick D, Haro JM, Bertsch J, et al：Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia：thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol 30：531-540, 2010

13)Alexander GC, Gallagher SA, Mascola A, et al：Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 20：177-184, 2011

14)Correll CU, Kane JM, Citrome LL：Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry 78：1136-1147, 2017

15)Sachdev P：Akathisia and Restless Legs Syndrome. Cambridge University Press, Cambridge, 1995

16)American Psychiatric Association：Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. (DSM-5). American Psychiatric Association, Washington D.C., p712, 2013(日本精神神経学会日本語版用語監修，髙橋三郎，大野裕監訳：DSM-5精神疾患の診断・統計マニュアル．医学書院，2014)

17)Ballesteros J, González-Pinto A, Bulbena A：Tardive dyskinesia associated with higher mortality in psychiatric patients：results of a meta-analysis of seven independent studies. J Clin Psychopharmacol 20：188-194, 2000

18)Youssef HA, Waddington JL：Morbidity and mortality in tardive dyskinesia：associations in chronic schizophrenia. Acta Psychiatr Scand 75：74-77, 1987

19)Gregory RP, Smith PT, Rudge P：Tardive dyskinesia presenting as severe dysphagia. J Neurol Neurosurg Psychiatry 55：1203-1204, 1992

20)Goldberg RJ, Morris PLP, Lidofsky S：Tardive dyskinesia presenting as gastrointestinal disorder. J Clin Psychiatry 51：253-254, 1990

21)Lumetti S, Ghiacci G, Macaluso GM, et al：Tardive dyskinesia, oral parafunction, and implant-supported rehabilitation. Case Rep Dent 2016：7167452, 2016

22)Bhimanil MM, Khan MM, Khan MF, et al：Respiratory dyskinesia-an under-recognized side-effect of neuroleptic medications. J Pak Med Assoc 61：930-932, 2011

23)Chiang E, Pitts WM Jr, Rodriguez-Garcia M：Respiratory dyskinesia：review and case reports. J Clin Psychiatry 46：232-234, 1985

24)Nieves JE, Stack KM, Harrison ME, et al：Dysphagia：a rare form of dyskinesia? J Psychiatr Pract 13：199-201, 2007

25)McEvoy J, Gandhi SK, Rizio AA, et al：Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual Life Res 28：3303-3312, 2019

26)Ascher-Svanum H, Zhu B, Faries D, et al：Tardive dyskinesia and the 3-year course of schizophrenia：results from a large, prospective, naturalistic study. J Clin Psychiatry 69：1580-1588, 2008

27)Othman Z, Ghazali M, Razak AA, et al：Severity of tardive dyskinesia and negative symptoms are associated with poor quality of life in schizophrenia patients. Int Med J 20：677-680, 2013

28)Paulsen JS, Caligiuri MP, Palmer B, et al：Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients：a prospective longitudinal study. Psychopharmacology(Berl) 123：307-314, 1996

29)Inada T, Yagi G, Kaijima K, et al：Clinical variants of tardive dyskinesia in Japan. Jpn J Psychiatry Neurol 45：67-71, 1991

30)Yassa R, Lal S：Respiratory irregularity and tardive dyskinesia. A prevalence study. Acta Psychiatr Scand 73：506-510, 1986

31)Hayashi T, Nishikawa T, Koga I, et al：Prevalence of and risk factors for respiratory dyskinesia. Clin Neuropharmacol 19：390-398, 1996

32)Chiu H, Shum P, Lau J, et al：Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. Am J Psychiatry 149：1081-1085, 1992

33)河野公範，宮岡剛，稲垣卓司，他：抗精神病薬により遅発性呼吸性ジスキネジアを生じた1例．精神医学 52：507-509, 2010

34)Greenberg DB, Murray GB：Hyperventilation as a variant of tardive dyskinesia. J Clin Psychiatry 42：401-403, 1981

35)Samie MR, Dannenhoffer MA, Rozek S：Life-threatening tardive dyskinesia caused by metroclopramide. Mov Disord 2：125-129, 1987

36)Muzyk AJ, Cvelich RG, Rivelli SK：Metoclopramide-induced tardive respiratory dyskinesia. J Neuropsychiatry Clin Neurosci 24：E37-E38, 2012

37)Horiguchi J, Shingu T, Hayashi T, et al：Antipsychotic-induced life-threatening “esophageal dyskinesia”. Int Clin Psychopharmacol 14：123-127, 1999

38)Macpherson R, Collis R：Tardive dyskinesia patients' lack of awareness of movement disorder. Br J Psychiatry 160：110-112, 1992

39)Emsley R, Niehaus DJH, Oosthuizen PP, et al：Subjective awareness of tardive dyskinesia and insight in schizophrenia. Eur Psychiatry 26：293-296, 2011

40)厚生労働省：重篤副作用疾患別対応マニュアル—ジスキネジア．2009　https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1c21.pdf (2020年11月18日閲覧)

41)Shinfuku N：Research on Asia Prescription Patterns(REAP)：focusing on data from Japan. Taiwan J Psychiatry(taipei) 28：71-85, 2014

42)下畑享良：ハンチントン舞踏病．福井次矢，高木誠，小室一成総編：今日の治療指針2019年版．医学書院，pp951-952, 2019

43)Bhidayasiri R, Fahn S, Weiner WJ, et al：Evidence-based guideline：treatment of tardive syndromes. Neurology 81：463-469, 2013

44)Bhidayasiri R, Jitkritsadakul O, Friedman JH, et al：Updating the recommendations for treatment of tardive syndromes：a systematic review of new evidence and practical treatment algorithm. J Neurol Sci 389：67-75, 2018

45)Taylor DM, Barnes TRE, Young AH：The Maudsley Prescribing Guidelines in Psychiatry 13th edition. Wiley Blackwell, Hoboken, pp90-93, 2018

46)日本神経精神薬理学会編集：統合失調症薬物治療ガイドライン．医学書院，pp117-132, 2016

47)Caroff SN, Mu F, Ayyagari R, et al：Hospital utilization rates following antipsychotic dose reductions：implications for tardive dyskinesia. BMC Psychiatry 18：306, 2018

48)Miyaoka T, Furuya M, Yasuda H, et al：Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia：an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 22：761-764, 2008

49)Hauser RA, Factor SA, Marder SR, et al：A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 174：476-484, 2017

50)Factor SA, Remington G, Comella CL, et al：The effects of valbenazine in participants with tardive dyskinesia：results of the 1-year：KINECT 3 extension study. J Clin Psychiatry 78：1344-1350, 2017

51)Anderson KE, Stamler D, Davis MD, et al：Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia(AIM-TD)：a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry 4：595-604, 2017

52)Fernandez HH, Stamler D, Davis MD, et al：Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psyciatry 90：1317-1323, 2019

53)American Psychiatric Association：Practice Guideline for the Treatment of Patients with Schizophrenia, Second Edition. American Psychiatric Association, Washington D.C., pp22-33, 2004

54)American Psychiatric Association：Practice Guideline for the Treatment of Patients with Schizophrenia, Third Edition. American Psychiatric Association, Washington D.C., pp7-15, 2020